Pharmasset (VRUS) Ratings, Price Targets

Pharmasset (VRUS) ratings and price targets.

Leerink downgraded Pharmasset from an “Outperform” rating to a “Market Perform” rating.

Canaccord Genuity downgraded Pharmasset from a “Buy” rating to a “Hold” rating.

JPMorgan Chase & Co. (NYSE:JPM) downgraded Pharmasset from an “Overweight” rating to a “Neutral” rating. They have a price target of $137.00 on the company.

Wells Fargo & Co. (NYSE:WFC) downgraded Pharmasset from an “Outperform” rating to a “Market Perform” rating.